IDEAYA Biosciences, Inc. Common Stock (IDYA) Stock
Key stats
- Market cap
- $3.16B
- Price / Earnings ratio
- -7.3x
- EPS (TTM)
- -$4.49
- Volume
- Loading
- 52-week high
- $42.68
- 52-week low
- $26.81
Source: third-party data provider, as of November 13, 2026
Compare with IDYA
Recent news

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
IDYA

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDYA

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDYA

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
IDYA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 45.48
- MACD 12/26/9
- -1.17
- EMA 9 of MACD
- -1.25
- MACD histogram
- 0.07
- SMA 50
- $35.80
- Price below SMA 50
- EMA 50
- $34.76
- Price below EMA 50
- SMA 200
- $33.87
- Price below SMA 200
- EMA 200
- $34.35
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
IDYA

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDYA

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDYA

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
IDYA

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
IDYA

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDYA

Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma
Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma
IDYA

Why Is IDYA Stock Surging Over 20% Overnight?
Why Is IDYA Stock Surging Over 20% Overnight?
IDYA

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
IDYA

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
IDYA
News tone: automated (AI) classification of the article's content, not a price prediction.
About IDEAYA Biosciences, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Yujiro S. Hata | Founder, President, CEO & Chairman | 1974 |
| Dr. Joshua Bleharski M.B.A., Ph.D. | Chief Financial Officer | 1975 |
| Mr. Andres Ruiz Briseno CPA | Chief Accounting Officer | 1986 |
| Dr. Michael A. White Ph.D. | Chief Scientific Officer | 1965 |
| Mr. Douglas B. Snyder | Chief Legal Officer | 1964 |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer | 1967 |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer | — |
| Ms. Francine Zelaya | Senior VP & Head of Human Resources | — |
| Mr. Mick O'Quigley | Senior Vice President of Medical Writing & Project Management | — |
| Mr. Daniel A. Simon | Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 45.48
- MACD 12/26/9
- -1.17
- EMA 9 of MACD
- -1.25
- MACD histogram
- 0.07
- SMA 50
- $35.80
- Price below SMA 50
- EMA 50
- $34.76
- Price below EMA 50
- SMA 200
- $33.87
- Price below SMA 200
- EMA 200
- $34.35
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $39.00
- Average
- $51.50
- High
- $66.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.9 | +10.6 | ||||||||||
| 2022 | -31.0 | -22.8 | -13.0 | -15.9 | +13.5 | +31.4 | +4.2 | -32.2 | +52.2 | +13.9 | +2.2 | +2.3 |
| 2023 | -2.0 | +2.3 | -21.2 | +24.0 | +18.0 | -1.8 | -2.2 | +31.0 | -9.4 | +5.2 | +8.9 | +12.5 |
| 2024 | +23.6 | +0.4 | -5.1 | -4.4 | -11.2 | -9.7 | +19.8 | -7.0 | -16.9 | -8.4 | -4.3 | -6.4 |
| 2025 | -3.2 | -13.0 | -14.4 | +36.3 | -2.8 | -0.9 | +15.3 | +1.2 | +6.8 | +16.4 | +13.6 | +0.8 |
| 2026 | -4.9 | -5.5 | +0.8 | -10.4 | +4.5 | +28.8 | -1.9 | +13.3 | -3.8 | -15.5 | +3.4 |



